Cargando…
Clinical Utility of Multigene Profiling Assays in Early-Stage Invasive Breast Cancer: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline
Objective: The purpose of this guideline is to determine the clinical utility of multigene profiling assays in individuals with early-stage invasive breast cancer. Methods: This guideline was developed by Ontario Health (Cancer Care Ontario)’s Program in Evidence-Based Care (PEBC) through a systemat...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029123/ https://www.ncbi.nlm.nih.gov/pubmed/35448187 http://dx.doi.org/10.3390/curroncol29040213 |
_version_ | 1784691797386067968 |
---|---|
author | Blanchette, Phillip Sivajohanathan, Duvaraga Bartlett, John Eisen, Andrea Feilotter, Harriet Pezo, Rossanna Turashvili, Gulisa Williams, Phillip |
author_facet | Blanchette, Phillip Sivajohanathan, Duvaraga Bartlett, John Eisen, Andrea Feilotter, Harriet Pezo, Rossanna Turashvili, Gulisa Williams, Phillip |
author_sort | Blanchette, Phillip |
collection | PubMed |
description | Objective: The purpose of this guideline is to determine the clinical utility of multigene profiling assays in individuals with early-stage invasive breast cancer. Methods: This guideline was developed by Ontario Health (Cancer Care Ontario)’s Program in Evidence-Based Care (PEBC) through a systematic review of relevant literature, patient- and caregiver-specific consultation and internal and external reviews. Recommendation 1: In patients with early-stage estrogen receptor (ER)-positive/human epidermal growth factor 2 (HER2)-negative breast cancer, clinicians should consider using multigene profiling assays (i.e., Oncotype DX, MammaPrint, Prosigna, EndoPredict, and the Breast Cancer Index) to help guide the use of systemic therapy. Recommendation 2: In patients with early-stage node-negative ER-positive/HER2-negative disease, clinicians may use a low-risk result from Oncotype DX, MammaPrint, Prosigna, EndoPredict/EPclin, or Breast Cancer Index assays to support a decision not to use adjuvant chemotherapy. Recommendation 3: In patients with node-negative ER-positive/HER2-negative disease, clinicians may use a high-risk result from Oncotype DX to support a decision to offer chemotherapy. A high Oncotype DX recurrence score is capable of predicting adjuvant chemotherapy benefit. Recommendation 4: In postmenopausal patients with ER-positive/HER2-negative tumours and one to three nodes involved (N1a disease), clinicians may withhold chemotherapy based on a low-risk Oncotype DX or MammaPrint score if the decision is supported by other clinical, pathological, or patient-related factors. Recommendation 5: The evidence to support the use of molecular profiling to select the duration of endocrine therapy is evolving. In patients with ER-positive disease, clinicians may consider using a Breast Cancer Index (H/I) high assay result to support a decision to extend adjuvant endocrine therapy if the decision is supported by other clinical, pathological, or patient-related factors. |
format | Online Article Text |
id | pubmed-9029123 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-90291232022-04-23 Clinical Utility of Multigene Profiling Assays in Early-Stage Invasive Breast Cancer: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline Blanchette, Phillip Sivajohanathan, Duvaraga Bartlett, John Eisen, Andrea Feilotter, Harriet Pezo, Rossanna Turashvili, Gulisa Williams, Phillip Curr Oncol Guidelines Objective: The purpose of this guideline is to determine the clinical utility of multigene profiling assays in individuals with early-stage invasive breast cancer. Methods: This guideline was developed by Ontario Health (Cancer Care Ontario)’s Program in Evidence-Based Care (PEBC) through a systematic review of relevant literature, patient- and caregiver-specific consultation and internal and external reviews. Recommendation 1: In patients with early-stage estrogen receptor (ER)-positive/human epidermal growth factor 2 (HER2)-negative breast cancer, clinicians should consider using multigene profiling assays (i.e., Oncotype DX, MammaPrint, Prosigna, EndoPredict, and the Breast Cancer Index) to help guide the use of systemic therapy. Recommendation 2: In patients with early-stage node-negative ER-positive/HER2-negative disease, clinicians may use a low-risk result from Oncotype DX, MammaPrint, Prosigna, EndoPredict/EPclin, or Breast Cancer Index assays to support a decision not to use adjuvant chemotherapy. Recommendation 3: In patients with node-negative ER-positive/HER2-negative disease, clinicians may use a high-risk result from Oncotype DX to support a decision to offer chemotherapy. A high Oncotype DX recurrence score is capable of predicting adjuvant chemotherapy benefit. Recommendation 4: In postmenopausal patients with ER-positive/HER2-negative tumours and one to three nodes involved (N1a disease), clinicians may withhold chemotherapy based on a low-risk Oncotype DX or MammaPrint score if the decision is supported by other clinical, pathological, or patient-related factors. Recommendation 5: The evidence to support the use of molecular profiling to select the duration of endocrine therapy is evolving. In patients with ER-positive disease, clinicians may consider using a Breast Cancer Index (H/I) high assay result to support a decision to extend adjuvant endocrine therapy if the decision is supported by other clinical, pathological, or patient-related factors. MDPI 2022-04-09 /pmc/articles/PMC9029123/ /pubmed/35448187 http://dx.doi.org/10.3390/curroncol29040213 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Guidelines Blanchette, Phillip Sivajohanathan, Duvaraga Bartlett, John Eisen, Andrea Feilotter, Harriet Pezo, Rossanna Turashvili, Gulisa Williams, Phillip Clinical Utility of Multigene Profiling Assays in Early-Stage Invasive Breast Cancer: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline |
title | Clinical Utility of Multigene Profiling Assays in Early-Stage Invasive Breast Cancer: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline |
title_full | Clinical Utility of Multigene Profiling Assays in Early-Stage Invasive Breast Cancer: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline |
title_fullStr | Clinical Utility of Multigene Profiling Assays in Early-Stage Invasive Breast Cancer: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline |
title_full_unstemmed | Clinical Utility of Multigene Profiling Assays in Early-Stage Invasive Breast Cancer: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline |
title_short | Clinical Utility of Multigene Profiling Assays in Early-Stage Invasive Breast Cancer: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline |
title_sort | clinical utility of multigene profiling assays in early-stage invasive breast cancer: an ontario health (cancer care ontario) clinical practice guideline |
topic | Guidelines |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029123/ https://www.ncbi.nlm.nih.gov/pubmed/35448187 http://dx.doi.org/10.3390/curroncol29040213 |
work_keys_str_mv | AT blanchettephillip clinicalutilityofmultigeneprofilingassaysinearlystageinvasivebreastcanceranontariohealthcancercareontarioclinicalpracticeguideline AT sivajohanathanduvaraga clinicalutilityofmultigeneprofilingassaysinearlystageinvasivebreastcanceranontariohealthcancercareontarioclinicalpracticeguideline AT bartlettjohn clinicalutilityofmultigeneprofilingassaysinearlystageinvasivebreastcanceranontariohealthcancercareontarioclinicalpracticeguideline AT eisenandrea clinicalutilityofmultigeneprofilingassaysinearlystageinvasivebreastcanceranontariohealthcancercareontarioclinicalpracticeguideline AT feilotterharriet clinicalutilityofmultigeneprofilingassaysinearlystageinvasivebreastcanceranontariohealthcancercareontarioclinicalpracticeguideline AT pezorossanna clinicalutilityofmultigeneprofilingassaysinearlystageinvasivebreastcanceranontariohealthcancercareontarioclinicalpracticeguideline AT turashviligulisa clinicalutilityofmultigeneprofilingassaysinearlystageinvasivebreastcanceranontariohealthcancercareontarioclinicalpracticeguideline AT williamsphillip clinicalutilityofmultigeneprofilingassaysinearlystageinvasivebreastcanceranontariohealthcancercareontarioclinicalpracticeguideline |